Back to top
more

Becton, Dickinson and Company (BDX)

(Real Time Quote from BATS)

$240.03 USD

240.03
327,405

+2.19 (0.92%)

Updated Jul 30, 2024 01:14 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 19% (203 out of 251)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Based in Franklin Lakes, NJ, Becton, Dickinson and Company (BDX) commonly known as BD, is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents. In fiscal 2019, BD’s revenues increased 8.2% to $17.29 billion. Earlier, BD’s operations consisted of three business segments: BD Medical, BD Diagnostics and BD Biosciences. However, the company’s organizational structure was realigned to form two principal business segments: BD Medical, BD Life Sciences and BD Interventional.

BD (BDX) Gears Up for Q4 Earnings: What's in the Offing?

by Zacks Equity Research

Continued strength in BD's (BDX) Interventional segment and Life Sciences segment's base business is expected to have driven Q4 sales.

Becton Dickinson (BDX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

Becton Dickinson (BDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AmerisourceBergen (ABC) Surpasses Q4 Earnings and Revenue Estimates

by Zacks Equity Research

AmerisourceBergen (ABC) delivered earnings and revenue surprises of 0.78% and 1.46%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

McKesson (MCK) Lags Q2 Earnings Estimates

by Zacks Equity Research

McKesson (MCK) delivered earnings and revenue surprises of -1.14% and 0.71%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

The Zacks Analyst Blog Highlights The Walt Disney, Broadcom, PayPal Holdings, Becton, Dickinson and Norfolk Southern

by Zacks Equity Research

The Walt Disney, Broadcom, PayPal Holdings, Becton, Dickinson and Norfolk Southern are part of the Zacks top Analyst Blog.

Here's How Much a $1000 Investment in Becton Dickinson Made 10 Years Ago Would Be Worth Today

by Zacks Equity Research

Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.

Sheraz Mian headshot

Top Research Reports for Walt Disney, Broadcom & PayPal

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including The Walt Disney Company (DIS), Broadcom Inc. (AVGO) and PayPal Holdings, Inc. (PYPL).

BD (BDX)-Biocorp's Latest Deal to Enhance Tracking Adherence

by Zacks Equity Research

BD's (BDX) newest agreement is expected to enable the care provision to transition to alternate settings and improve chronic disease outcomes.

BD's (BDX) New Cloud Software Solution to Boost Lab Workflow

by Zacks Equity Research

BD's (BDX) latest launch is expected to provide scientists with an integrated ecosystem that enables optimization of panel design, collaboration and analysis.

    BD's (BDX) Latest Monkeypox PCR Assay Commercially Available

    by Zacks Equity Research

    BD's (BDX) new molecular RUO PCR assay is expected to aid in better managing the ongoing global monkeypox outbreak.

      Quest Diagnostics (DGX) & Peers Progress With Monkeypox Testing

      by Zacks Equity Research

      Quest Diagnostics in its latest media report notes that demand for COVID-19 molecular diagnostic testing declined in August compared to the prior month.

        BD's (BDX) Latest PFS Launch to Boost Production Efficiencies

        by Zacks Equity Research

        BD's (BDX) newest product offering is expected to set a new standard in performance for vaccine PFS with new and strict specifications for improved production efficiencies.

        Implied Volatility Surging for BD (BDX) Stock Options

        by Zacks Equity Research

        Investors need to pay close attention to BD (BDX) stock based on the movements in the options market lately.

        Here's Why You Should Hold on to BD (BDX) Stock for Now

        by Zacks Equity Research

        Investors continue to be optimistic about BD (BDX) owing to a few regulatory approvals and strategic deals.

        BD's (BDX) Latest Collaboration to Boost Patient Outcome

        by Zacks Equity Research

        BD's (BDX) tie-up with Accelerate Diagnostics is expected to strengthen the fight to combat the global threat of antimicrobial resistance, thereby boosting patient care.

        BD (BDX) Ties Up With LabCorp to Boost Patient Outcome

        by Zacks Equity Research

        BD's (BDX) latest partnership is expected to provide life-changing treatments for cancer and other diseases, thereby improving patient care.

        Zimmer Biomet (ZBH) Sees Business Recovery, Global Growth

        by Zacks Equity Research

        Zimmer Biomet (ZBH) revenues ride on continued execution along with strong COVID recovery across most markets.

        Cardiovascular Systems (CSII) Q4 Earnings, Revenues Miss Mark

        by Zacks Equity Research

        According to Cardiovascular Systems (CSII), strong sequential growth in each of its segments is due to procedure recovery, focused commercial strategies and the launch of products.

        Nevro (NVRO) Q2 Earnings Beat Estimates, FY22 View Revised

        by Zacks Equity Research

        Nevro's (NVRO) worldwide revenues improve on a year-over-year basis in Q2, partly owing to robust domestic performance.

        QuidelOrtho (QDEL) Q2 Earnings Miss, Provides FY22 View

        by Zacks Equity Research

        QuidelOrtho's (QDEL) robust performance across majority of its business units and geographies drives its second-quarter 2022 top line.

        AMN Healthcare (AMN) Q2 Earnings, Revenues Beat Estimates

        by Zacks Equity Research

        AMN Healthcare's (AMN) robust Q2 results demonstrate its segmental strength.

        BD (BDX) Beats on Q3 Earnings and Revenues, Raises FY22 View

        by Zacks Equity Research

        The majority of BD's (BDX) core units witness strong revenue growth in the fiscal third quarter.

        Becton Dickinson (BDX) Surpasses Q3 Earnings and Revenue Estimates

        by Zacks Equity Research

        Becton Dickinson (BDX) delivered earnings and revenue surprises of 6.83% and 4.02%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

        Debanjana Dey headshot

        Medical Device Stocks Earnings on Aug 4: BDX, ABMD, AMN & DOCS

        by Debanjana Dey

        The Medical Device companies' Q2 results are likely to reflect strength in customer demand. Let's see how BDX, ABMD, AMN and DOCS are placed ahead of their earnings releases.

        Zacks Industry Outlook Highlights Becton, Dickinson and Company, Patterson Companies and SmileDirectClub

        by Zacks Equity Research

        Becton, Dickinson and Company, Patterson Companies and SmileDirectClub are part of Zacks Industry Outlook article.